Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
University of Saskatchewan currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is characterized by a distributed prosecution environment, as the active cases are assigned to 2 distinct examiners across 2 distinct art units. Such a distribution suggests that the university's biotechnological innovations are diverse enough to fall under different technical classifications at the patent office, requiring a strategy that accounts for multiple sets of examiner expectations and art unit guidelines.
The busiest examiner for this portfolio is CHEN, STACY BROWN, who is responsible for 1 pending office action. Given that there are 2 distinct examiners in total, the workload is split such that no single examiner dominates the prosecution of the university's current applications. For a practitioner, this means that the outcomes for the 2 pending office actions will likely be independent of one another, as they are being reviewed by different individuals in different art units. This lack of concentration requires a tailored approach for each filing to address the specific technical nuances identified by each examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
| BECKHARDT, LYNDSEY MARIE | 1 | 27.8% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17156167 | NEURONAL AGONISTS AND ISOTONIC OR HYPERTONIC SALINE FOR TREATING RESPIRATORY DISEASES | BECKHARDT, LYNDSEY MARIE | 1d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17156167 | NEURONAL AGONISTS AND ISOTONIC OR HYPERTONIC SALINE FOR TREATING RESPIRATORY DISEASES | BECKHARDT, LYNDSEY MARIE | 1d overdue |
| 18556668 | COMPOSITIONS AND METHODS FOR PREVENTING RSV AND PIV3 INFECTIONS | CHEN, STACY BROWN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556668 | COMPOSITIONS AND METHODS FOR PREVENTING RSV AND PIV3 INFECTIONS | CHEN, STACY BROWN | 1672 | §112 | Non-Final OA | — | Pending | Oct 21, 2023 |
| 17156167 | NEURONAL AGONISTS AND ISOTONIC OR HYPERTONIC SALINE FOR TREATING RESPIRATORY DISEASES | BECKHARDT, LYNDSEY MARIE | 1613 | §103 | Final Rejection | 1d overdue | Pending | Jan 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of Saskatchewan has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Stacy Brown Chen has the most, with 1 of University of Saskatchewan's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
